GENEVA: The World Health Organisation (WHO) has approved the Covaxin on Wednesday, the COVID-19 vaccine developed by Indian pharmaceutical firm Bharat Biotech Ltd, for emergency use, adding to a growing portfolio of vaccines validated by the organisation.
An official statement from WHO confirmed the speculations circulating in the media:
The vaccine was approved in two doses, with an interval of four weeks in all the age groups above 18 and all. Although the organisation didn’t give any approval to the vaccine maker that the vaccine could be used on Children and pregnant women, as there was no available data on vaccination with the Covaxin are insufficient.
Bharat Biotech applied in April to get an emergency authorisation by the WHO and provided the relevant data on July 6, which involves assurances about the vaccine’s safety, efficacy as well its production facilities. The Geneva-based global health body called a meeting on November 3 whether to give approval to Bharat Biotech or ask them to get more clarity on the data for the vaccine.
The Indian Government’s constant push over Covaxin for getting approval from WHO will help the Indian drug companies to come to par, with the United States and United Kingdom-based drug companies. Australia became the first QUAD country to have approved the double-dose Covaxin in their country. The announcement by the Australian Government caught the attention of Prime Minister Modi, who took to Twitter and thanked Prime Minister of Australia Scott Morrison for the brewing partnership of both countries.
Apart from Covishield and Covaxin, the WHO has a portfolio of vaccines produced by Pfizer, Johnson & Johnson-Janssen, Moderna, and China’s Sinopharm for emergency use.